Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Qualizyme Diagnostics has developed patented rapid diagnostic tests that detect early-stage infections by measuring the activity of specific anti-bacterial enzymes. Their lead wound infection test demonstrated high sensitivity and specificity in clinical studies, including ICU settings, with 100% sensitivity and 97% specificity reported for an airway infection diagnostic. The company is also developing rapid COVID‑19 tests based on direct viral particle detection rather than RNA or antibody methods. Several patents have been filed covering their core technology, including applications in synovial fluid diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Qualizyme Diagnostics.